Skip to main content
    N

    Neumora Therapeutics, Inc. (NMRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.43
    +0.07 (+20.45%)

    Market Cap: $80.23M

    Last updated: Oct 16, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(6/12)
    Avg Surprise
    -13.37%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.19
    Range$-0.21 - $-0.17
    9 analysts
    EPS Revisions
    4
    0
    7d
    4
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.21+7.3%
    60d ago$-0.21+6.3%
    30d ago$-0.190.0%
    7d ago$-0.190.0%
    Current$-0.19
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.13
    Range$-0.19 - $0.09
    9 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.13---
    Sep 26EST
    		-$-0.19---
    Jun 26
    Reported Aug 14
    		$-0.23$-0.23+0.00%Beat+30.3%
    Mar 26
    Reported May 7
    		$-0.30$-0.31+3.23%Beat+28.6%
    Dec 25
    Reported Mar 16
    		$-0.35$-0.47+25.53%Beat+5.4%
    Sep 25
    Reported Nov 6
    		$-0.35$-0.34-2.94%Miss+22.2%
    Jun 25
    Reported Aug 6
    		$-0.33$-0.37+10.81%Beat+10.8%
    Mar 25
    Reported May 12
    		$-0.42$-0.46+8.70%Beat-23.5%
    Dec 24
    Reported Mar 3
    		$-0.37$-0.44+15.91%Beat+47.9%
    Sep 24
    Reported Nov 12
    		$-0.45$-0.38-18.42%Miss+60.5%
    Jun 24
    Reported Aug 6
    		$-0.37$-0.36-2.78%Miss-33.0%
    Mar 24
    Reported May 7
    		$-0.34$-0.32-6.25%Miss-
    Dec 23
    Reported Mar 7
    		$-0.71$-0.55-29.09%Miss-
    Sep 23
    Reported Nov 1
    		$-1.14$-0.43-165.12%Miss-
    Jun 23
    Reported Aug 30
    		$-0.28$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.35EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-187.10%ROIC-217.02%
    Financial Health
    Debt/Equity1.19xInterest Coverage-32.75x
    Current Ratio4.50xQuick Ratio4.50x
    Trading Statistics
    Beta2.98Avg Volume2.49M
    52-Week High$3.6552-Week Low$0.32

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.45
    SMA 20$0.57
    SMA 50$1.06
    SMA 200$1.87
    EMA 10$0.46
    EMA 20$0.59
    EMA 50$0.93
    EMA 200$1.55

    MACD

    Line: -0.19Signal: -0.20Hist: 0.01

    ADX

    ADX: 56.5+DI: 12.2-DI: 37.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down96.0
    PSAR$0.32

    Bollinger Bands

    Upper Band$0.83
    Lower Band$0.30
    %B Position9370%(Upper)
    Band Width0.24

    RSI (14-Day)

    Oversold
    26.7

    Momentum Oscillators

    Stoch %K11.9
    Stoch %D6.1
    Williams %R-74.1
    ROC (10d)-22.4%
    Momentum-0.12
    CCI (20d)-89.1
    MFI (14d)36.5

    Volatility Measures

    ATR (14d)$0.08(18.7%)
    StdDev (20d)0.13
    Hist Vol131.7%(High)

    Volume Flow

    VWAP$0.42
    OBV50.1M
    AD Line6.4M
    CMF (20d)-0.127

    Volume Metrics

    Avg Vol (20d)2.4M
    Vol Ratio2.6x(High)
    VWMA (20d)$0.57

    Pivot Points

    R3$0.48
    R2$0.44
    R1$0.40
    Pivot Point$0.36
    S1$0.31
    S2$0.27
    S3$0.23

    Advanced Oscillators

    TSI-59.00
    Ultimate Osc37.2
    KST-556.16

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0$318,000$0$0$0$166,000$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0$-166,000$0
    Operating Expenses$42.19M$52.86M$58.48M$57.70M$54.04M$70.94M$62.92M$76.65M$63.82M$60.07M$114.00M$56.86M
    R&D$29.28M$38.60M$44.67M$45.52M$38.72M$52.15M$45.91M$60.63M$48.63M$45.76M$102.77M$41.60M
    SG&A$12.91M$14.27M$13.81M$12.18M$15.32M$18.79M$17.01M$16.02M$15.19M$14.32M$11.24M$15.26M
    Operating Income$-42,190,000$-52,864,000$-58,480,000$-57,700,000$-54,040,000$-70,936,000$-62,922,000$-76,646,000$-63,822,000$-60,074,000$-114,004,000$-56,864,000
    Interest Income$935,000$1.23M$1.77M$1.69M$2.25M$3.07M$4.09M$4.21M$5.27M$6.37M$5.65M$3.84M
    Interest Expense$1.82M$1.85M$970,000$747,000$436,000$0$0$0$0$0$30.08M$0
    Income Before Tax$-43,082,000$-53,428,000$-59,450,000$-56,755,000$-52,706,000$-67,887,000$-58,819,000$-72,494,000$-58,575,000$-53,721,000$-144,087,000$-53,027,000
    Income Tax Expense$0$30,000$0$0$25,000$105,000$0$53,000$125,000$0$268,000$0
    Net Income$-43,082,000$-53,458,000$-59,450,000$-56,755,000$-52,731,000$-67,992,000$-58,819,000$-72,547,000$-58,700,000$-53,721,000$-108,730,000$-53,027,000
    EBITDA$-41,796,000$-52,379,000$-59,256,000$-54,969,000$-54,198,000$-70,804,000$-62,750,000$-76,547,000$-63,686,000$-59,928,000$-113,942,000$-56,692,000
    EBIT$-42,197,000$-52,805,000$-58,749,000$-57,693,000$-54,520,000$-70,961,000$-62,907,000$-76,703,000$-63,846,000$-60,086,000$-114,108,000$-56,865,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NMRA

    News

    Neumora Therapeutics (NASDAQ:NMRA) Cut to Strong Sell at Wall Street Zen

    Wall Street Zen downgraded Neumora Therapeutics (NASDAQ:NMRA) to "strong sell," though other analysts maintain a "Moderate Buy" consensus with a $6.57 target price. The company's shares opened at $0.48...

    MarketBeat•10/10/26•Bearish

    Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Moderate Buy" by Analysts

    Analysts have issued a "Moderate Buy" rating for Neumora Therapeutics (NASDAQ:NMRA), with an average 12-month price target of $6.57, despite several recent target reductions. The company's shares opened at $0.73...

    MarketBeat•9/19/26•Somewhat-Bearish

    BlackRock Inc. Buys Shares of 7,791,869 Neumora Therapeutics, Inc. $NMRA

    BlackRock Inc. has purchased 7,791,869 shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) during the second quarter, a new position valued at approximately $13.25 million...

    MarketBeat•9/4/26•Neutral

    Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Moderate Buy" from Analysts

    Neumora Therapeutics (NASDAQ:NMRA) has received an average "Moderate Buy" rating from analysts, with a consensus price target of $6.57, despite recent reductions by some firms. The company's shares opened at $1.52...

    MarketBeat•8/25/26•Somewhat-Bearish

    2,559,090 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by ICONIQ Capital LLC

    ICONIQ Capital LLC has purchased 2,559,090 shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA), amounting to a 1.38% stake valued at approximately $4.35 million. Other institutional investors have also increased their...

    MarketBeat•8/24/26•Neutral

    NMRA Valuation and Fair Value

    P/E
    -0.3x
    P/B
    1.8x
    See GNG's fair value

    NMRA Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -217.0%
    ROE
    -187.1%

    NMRA Competitors

    CompanyTicker
    Sera Prognostics IncSERA
    NeOnc Technologies Holdings, Inc. Common StockNTHI
    CareCloud, Inc.CCLD
    Cardiff Oncology IncCRDF
    Equillium IncEQ
    Lixte Biotechnology Holdings IncLIXT
    Hyperfine IncHYPR
    ProMIS Neurosciences Inc.PMN

    Sector: Healthcare

    NMRA Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    2
    Buy
    5
    Hold
    1
    Sell
    0
    Strong Sell
    1

    NMRA Bull Case vs Bear Case

    Bull case

    • 77.8% of NMRA's analyst ratings are Buy or Strong Buy.

    NMRA Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    5.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.19
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 2 down

    Frequently Asked Questions About NMRA

    Does NMRA pay dividends?

    Neumora Therapeutics, Inc. (NMRA) does not currently pay a regular dividend.

    What is NMRA's market cap?

    Neumora Therapeutics, Inc. (NMRA) has a market capitalization of $80.23M with a current stock price of $0.43.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In